This study, conducted by the AMPLIFY-EXT Investigators, aimed to evaluate the efficacy and safety of extended anticoagulation therapy with apixaban in patients with venous thromboembolism (VTE) who had completed 6 to 12 months of initial anticoagulation therapy. The randomized, double-blind trial compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo over a 12-month period. The primary efficacy outcome was the composite of symptomatic recurrent VTE or death from any cause. The results showed that both doses of apixaban significantly reduced the risk of this primary outcome compared to placebo (7.2% and 7.0% reduction, respectively, with 95% CI 5.0 to 9.3 and 4.9 to 9.1, P<0.001 for both comparisons). Major bleeding rates were low and similar across all groups, with no significant differences between the 2.5 mg and 5 mg doses. The study concluded that extended anticoagulation with apixaban at either dose effectively reduced the risk of recurrent VTE without increasing the rate of major bleeding, providing a rationale for continuing anticoagulation therapy for an additional 12 months in patients with VTE.This study, conducted by the AMPLIFY-EXT Investigators, aimed to evaluate the efficacy and safety of extended anticoagulation therapy with apixaban in patients with venous thromboembolism (VTE) who had completed 6 to 12 months of initial anticoagulation therapy. The randomized, double-blind trial compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo over a 12-month period. The primary efficacy outcome was the composite of symptomatic recurrent VTE or death from any cause. The results showed that both doses of apixaban significantly reduced the risk of this primary outcome compared to placebo (7.2% and 7.0% reduction, respectively, with 95% CI 5.0 to 9.3 and 4.9 to 9.1, P<0.001 for both comparisons). Major bleeding rates were low and similar across all groups, with no significant differences between the 2.5 mg and 5 mg doses. The study concluded that extended anticoagulation with apixaban at either dose effectively reduced the risk of recurrent VTE without increasing the rate of major bleeding, providing a rationale for continuing anticoagulation therapy for an additional 12 months in patients with VTE.